Drug reservoir for separate storage of substances

By introducing a compressible gas volume in the proximal chamber of dual chamber drug delivery devices, the pistons are released sequentially, reducing activation forces and enabling efficient, comfortable, and cost-effective drug delivery.

JP2024167224AInactive Publication Date: 2024-12-03NOVO NORDISK AS
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024128668
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-28
Filing Date
2024-08-05
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing dual chamber drug delivery devices face issues with high activation forces due to static friction between pistons, leading to uncomfortable user experiences and potential chemical reactions or device failure, especially in auto-injectors.

Method used

Incorporating a non-liquid bound gas volume in the proximal chamber to make it compressible, allowing pistons to be released sequentially, reducing the required activation force and enabling the use of weaker springs in auto-injectors.

Benefits of technology

The solution reduces the force needed for drug ejection, minimizing user discomfort and device stress, while allowing for cost-effective and reliable delivery of multiple substances through a single needle.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167224000001_ABST
    Figure 2024167224000001_ABST
Patent Text Reader

Abstract

To provide a drug reservoir for use in an injection device for delivery of two or more substances.SOLUTION: The present invention provides a drug reservoir 1 comprising: a reservoir body 2 extending between a distal end 4 and an open proximal end 7; a front piston 8 arranged in a pre-use position within the reservoir body between the outlet end and the proximal end; a rear piston 9 arranged within the reservoir body between the front piston and the proximal end; a front chamber 10 defined by the outlet end, a first portion of the reservoir body and the front piston, the front chamber holding a first liquid substance; a rear chamber 11 defined by the front piston, a second portion of the reservoir body and the rear piston, the rear chamber holding a second liquid substance 19 including a proximal gas volume 12; and a bypass channel 3 allowing a fluid flow past the front piston in an advanced position of the front piston.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to reservoirs for medical use, and in particular to reservoirs having two or more chambers. [Background technology]

[0002] Within some medical therapeutic areas, combination therapy involving the co-administration of at least two agents is advantageous due to synergistic or additive effects. For example, in diabetes care, in the management of type 2 diabetes, the simultaneous use of certain insulin and glp-1 products has been shown to increase HbA 1c It has been shown to reduce levels, thereby improving glycemic control.

[0003] Many drugs must be administered parenterally to be effective in the body, and some of these, such as insulin and GLP-1, may require one or more doses to be delivered subcutaneously daily. Subcutaneous drug delivery is often associated with discomfort, as many people dislike the idea of ​​inserting a needle through the skin. An unknown number of people even suffer from needle phobia, and these people have a strong desire to escape, especially from multiple daily injection therapy.

[0004] Therefore, one attractive scenario is to reduce the number of skin penetrations required by administering drugs simultaneously or substantially simultaneously through a single injection needle.In some cases, this can be achieved by co-formulation of active ingredients, and the co-formulated product is administered using a conventional injection device.In other cases, for example, when the active ingredients are not suitable for co-formulation, the individual substances are stored in separate chambers of a dual-chamber or multi-chamber storage device, which can be simultaneously or sequentially expressed through a single injection needle by using a dedicated expression means.

[0005] US Patent No. 5,399,633 discloses an embodiment of a dual chamber storage device in the form of an autoinjector having a cartridge with a fixedly attached hypodermic needle. In the pre-use state of the device, the cartridge holds a forward liquid medicament in the forward chamber and a rearward liquid medicament in the rearward chamber. The two liquids are separated by an intermediate piston, and the rearward chamber is sealed proximally by the rearward piston. In use, in response to the release of the stressed spring, it urges the plunger forward, pushing the rearward piston and pressurizing the rearward liquid medicament to transmit the movement of the rearward piston to the intermediate piston. Eventually, as the spring continues to provide a forward bias to the plunger, this results in the ejection of the forward liquid medicament through the hypodermic needle and then the ejection of the rearward liquid medicament through a distally disposed bypass section.

[0006] US Patent No. 5,399,633 discloses an embodiment of a dual chamber storage device in the form of a manually operated mixing device with a piston coupling arrangement that allows for an aspiration procedure to ensure proper insertion of an associated IV infusion needle. In the pre-use state of the device, a dry drug or liquid is held in the front chamber and a liquid is held in the rear chamber. The two substances are separated by a front piston, and the rear chamber is sealed proximally by a rear piston through which the piston rod extends. In use, the piston rod is manually advanced, disconnecting the rear piston and pressurizing the rear chamber liquid to transfer the movement of the rear piston to the front piston. As the user continues to push the piston rod forward, the front piston enters the bypass section and becomes stuck as pressure forces the rear chamber liquid into the bypass, past the front piston and into the front chamber. In the front chamber, the two substances mix as the rear chamber compresses. When the rear piston finally reaches the front piston and the substances are completely mixed, the user can expel the mixed substance by continued advancement of the piston rod.

[0007] A common drawback of such devices is the fact that over time during storage, the piston material tends to adhere to the reservoir material, meaning that significant static friction must be overcome to initiate drug mixing and / or ejection. Due to the incompressibility of the liquid in the rear chamber, the two pistons move simultaneously until the front piston reaches the bypass section. As a result, the force required to overcome this static friction is actually the sum of the forces required to release the individual pistons.

[0008] In the case of a manually driven piston rod, the sudden shift from static to kinetic friction when the piston is released is likely to cause a sudden forward movement of the piston as the user attempts to compensate for the sudden acceleration by drastically reducing the force input. Not only is this an unpleasant user experience, but it may actually lead to an excessively rapid transfer of rear chamber liquid to the front chamber. If the front chamber is reconstituted carrying a dry powder, the transfer process may even lead to undesirable foaming.

[0009] In the context of spring-driven injection devices, such as the auto-injector of US Pat. No. 5,999,633, the spring needs to be relatively strong to ensure availability of sufficient release force. The drawback of this is that when friction becomes dynamic, the power available for actual drug ejection can be very high, leading to uncomfortably fast delivery. Furthermore, a strong spring requires stronger mating injection device parts to avoid creep or breakage during potential medium or long-term storage periods in a preloaded state, increasing both the cost and weight of the injection device. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] U.S. Patent No. 4,394,863 (Survival Technology, Inc.) [Patent Document 2] International Patent Publication No. 2010 / 139793 (Novo Nordisk A / S) Summary of the Invention

[0011] It is an object of the present invention to obviate or reduce at least one disadvantage of the prior art, or to provide a useful alternative to the prior art solutions.

[0012] In particular, it is an object of the present invention to provide a drug reservoir for use in an injection device for delivering two or more substances, where pistons arranged in series within the drug reservoir can be moved by the application of reduced force.

[0013] It is a further object of the present invention to provide a drug delivery device for delivering multiple substances through a single needle interface based on a relatively low force input.

[0014] It is also an object of the present invention to provide a cost-effective automatic injection device for delivery of multiple early stage separated substances.

[0015] It is a still further object of the present invention to provide a method for filling a drug reservoir having two or more chambers.

[0016] In the present disclosure, aspects and embodiments are described that address one or more of the above objectives and / or that address objectives that are apparent from the following text. [Means for solving the problem]

[0017] In one aspect, the present invention provides a drug reservoir as claimed in claim 1.

[0018] Thus, there is provided a drug reservoir comprising a reservoir body extending along a reference axis between a proximal end and an outlet end, a front piston disposed in the reservoir body in a pre-use position between the proximal end and the outlet end, a rear piston disposed in the reservoir body between the front piston and the proximal end, a distal chamber defined by the outlet end, a first portion of the reservoir body, and the front piston, a proximal chamber defined by the front piston, a second portion of the reservoir body, and the rear piston, and a bypass means allowing fluid flow past the front piston at a particular advanced position of the front piston (i.e., distal to the pre-use position). The distal chamber holds a first content, for example comprising a distal liquid volume or dry powder, and the proximal chamber holds a second content, including a proximal liquid volume and a proximal gas volume. The proximal gas volume is the volume of non-liquid bound gas, i.e., free gas not incorporated at the molecular level in the liquid, within a volume range having a preset minimum value.

[0019] The non-liquid bound gas exists as a gas volume between the surface portion of the proximal liquid volume and the surface portion of the proximal chamber, or as gas bubbles in the proximal liquid volume. The non-liquid bound proximal gas volume provides elasticity to the proximal chamber in the sense that the second contents are compressible, as opposed to when the second contents consist of only liquid. This has the effect that the two pistons are released sequentially, rather than simultaneously. When a force of sufficient magnitude is applied to the rear piston, it can be released from the inner wall of the reservoir body, whereby the force resisting the movement of the rear piston will shift from a static friction force to a lower kinetic friction force before the applied force is transmitted to the front piston through the second contents. Thus, the release force required to move the two pistons is lower than if the second contents were incompressible and two static friction forces had to be overcome simultaneously.

[0020] As a result, when used in a drug delivery device, the drug reservoir provides a lower activation force during the drug ejection operation. For an automatic injection device, for example, this means that a less powerful spring can be employed to drive the drug ejection mechanism. A less powerful spring, in a pre-loaded state, places less strain on the mating device components, reducing the risk of creep or breakage, and / or allowing the use of less deformation-resistant materials and / or configurations, thereby reducing the cost of the drug delivery device.

[0021] The predetermined or preset minimum value of the volume range in which the proximal gas volume lies reflects the amount of gas required to obtain the above-mentioned effect. This minimum value may depend on the lateral dimensions of the reservoir body and the design of the rear piston. For drug reservoirs of types and sizes commonly used in injection or infusion therapy, as achieved by subcutaneous self-administration of drugs, including reservoirs defined in ISO11040-4(2015): Prefilled Syringes - Part 4: Glass Barrels for Injections and Ready-to-Use Fillable Syringes, (e.g., employing a rubber piston with an external configuration as defined in ISO11040-5(2012): Prefilled Syringes - Part 5: Plunger Stoppers for Injections), the inventors have established that a minimum gas volume of 15 μl (e.g., for a standard 1 ml long PFS with an internal diameter of 6,35 mm) is required to provide sufficient elasticity in the proximal chamber, which allows for the sequential release of the two pistons.

[0022] The volume range may further have a predetermined or preset maximum value, in which case the volume range is a predetermined closed volume range. The maximum value may reflect, for example, the maximum amount of gas guaranteed not to cause stability issues with the proximal liquid volume and / or the manufacturer's particular practical considerations with respect to the physical dimensions of the final product.

[0023] The maximum gas volume that satisfies the requirements for the physical size of the drug reservoir may be, for example, 200 μl, 100 μl, 75 μl, or 50 μl.

[0024] The optimal volume range can be established or approximated taking into account the aforementioned requirements as well as the effects produced by a particular proximal gas volume. The inventors have determined that in some cases, a predetermined volume range [15 μl; 200 μl] is preferred, while in other cases, for example, a predetermined volume range [20 μl; 50 μl] is preferred.

[0025] In some embodiments of the invention, the first contents include a distal liquid volume and a distal (non-liquid bound) gas volume, where the distal gas volume is smaller than the proximal gas volume.

[0026] The distal liquid volume may contain or include a first drug substance and the proximal liquid volume may contain or include a second drug substance.

[0027] In some embodiments of the invention, the proximal gas volume comprises air, which is particularly attractive in the context of drug reservoir manufacturing, as the reservoir body can be filled in a conventional clean room environment.

[0028] In other embodiments of the invention, the proximal gas volume contains an inert gas to reduce the risk of undesired chemical reactions with the proximal liquid volume, in these embodiments, the reservoir body may be filled in a clean room environment with the inert gas.

[0029] The drug reservoir may be, for example, a cartridge-type reservoir, with a pierceable septum closing the outlet end, or may be a syringe-type reservoir. In the latter case, the drug reservoir may further include a staked hollow needle, i.e., a hollow needle fixedly disposed at the outlet end and fluidly connected with the distal chamber. The hollow needle may be sealed by a removable plug.

[0030] The bypass means may comprise a bypass channel, for example as conventionally known from dual chamber pharmaceutical containers such as those disclosed in US Pat. No. 4,394,863.

[0031] In another aspect of the invention, there is provided a drug delivery device comprising a drug reservoir as described above. The drug delivery device may further comprise a dose ejection structure for pressurizing the proximal chamber. The dose ejection structure may comprise an actuatable piston rod adapted to transmit an ejection force to the rear piston.

[0032] The piston rod may be attached or attachable to the rear piston and adapted for direct manipulation by a user of the drug delivery device, or the drug reservoir may be integrated into, for example, the housing of the drug delivery device and the piston rod may be operable via other components within the housing.

[0033] The dose ejection structure may be powered by a spring member operatively connected to the piston rod and adapted to store releasable energy to bias the piston rod towards the outlet end, thereby providing an automatic drug delivery device capable of effecting drug ejection with minimal user effort.

[0034] The drug delivery device may further include a retaining structure that holds the spring member in a tensioned state when activated, and a sleeve member extending axially along a portion of the housing and including a release structure, the sleeve member configured to be displaced proximally relative to the housing and the retaining structure from a first position in which the retaining structure is enabled, to a second position in which the retaining structure is disabled by the release structure, resulting in the stored energy being released from the spring member.

[0035] In the first position, the sleeve member may extend a distance beyond the outlet end such that a hollow needle disposed at the outlet end is covered by a distal end portion thereof, whereby the sleeve member may act as a combined needle shield and trigger the tensioned spring.

[0036] Thus, by simply placing the sleeve on the skin and pushing the housing towards the skin, the user will initiate an automatic injection as the retention structure is disabled, thereby causing the release of stored energy from the spring, which will be used to urge the piston rod distally relative to the housing. During movement of the sleeve member to the second position, the release structure will apply a force to the rear piston, thereby causing a series of events including compression of the second contents and release of the rear piston from the inner wall of the reservoir body, further pressurization of the second contents and release of the front piston from the inner wall of the reservoir body, axial displacement of the proximal chamber until the front piston reaches a specific advanced position during which a portion of the first contents may be expelled through the outlet end, compression of the proximal chamber as the second contents pass through the front piston via the bypass means, and finally emptying or substantially emptying of the distal chamber.

[0037] Notably, the spring size and power required to achieve this may be less than prior art drug reservoirs due to the initial presence of a proximal gas volume, as discussed above.

[0038] In a further aspect of the invention, a method of filling a drug reservoir including a generally cylindrical body having a bypass section, a closed outlet end, and an open end is provided, the method comprising: (i) disposing the drug reservoir at least substantially vertically with the open end facing upward; (ii) introducing a first liquid volume into the drug reservoir through the open end such that a first interior portion of the generally cylindrical body including the bypass section is covered by liquid at the vertical position of the drug reservoir with the open end facing upward; and (iii) inserting a first piston into the generally cylindrical body in a first subatmospheric pressure environment to a first piston position at least substantially adjacent a free surface of the first liquid volume; (iv) introducing a second liquid volume into the drug reservoir through the open end; and (v) inserting a second piston into the generally cylindrical body to a second piston position in a second subatmospheric pressure environment of ambient gas, thereby establishing a rear chamber, the second piston position being determined such that the rear chamber holds the second liquid volume and the rear chamber gas volume is within a volume range having a predetermined minimum value.

[0039] The first sub-atmospheric pressure environment establishes a negative pressure in the front chamber that draws the first piston towards the free surface of the first liquid volume, ensuring that the current front chamber gas volume is minimized.

[0040] The second sub-atmospheric pressure environment may be established in an ambient gas selected by the manufacturer according to the composition of the second liquid volume, for example air or an inert gas, the latter of which may be selected to minimize the risk of undesired chemical reactions with the second liquid volume.

[0041] The second sub-atmospheric environment ensures that a negative pressure is established in the rear chamber which can be controlled to position the second piston at a desired location within the generally cylindrical body, thereby providing for the presence of gas at a predetermined minimum amount in terms of the position of the first piston and the volume of second liquid taken in.

[0042] In some exemplary embodiments of the invention, the predetermined minimum is 15 μl, hi other exemplary embodiments of the invention, the predetermined minimum is 20 μl.

[0043] In step (v), the second piston position may be determined such that the gas volume in the rear chamber is within a predetermined closed volume range, i.e. such that the volume range further has a predetermined maximum value.

[0044] In some exemplary embodiments of the invention, the predetermined maximum is 200 μl, hi other exemplary embodiments of the invention, the predetermined maximum is 50 μl.

[0045] The first and / or second pistons may be disposed at the desired piston position using an insertion tube having an outer diameter smaller than the inner diameter of the generally cylindrical body such that the insertion tube may be introduced into the generally cylindrical body through its open end without establishing physical contact with the generally cylindrical body, the piston in question being previously disposed to slide within the insertion tube, which is inserted into the generally cylindrical body to a position proximal to the desired piston position, whereupon the piston slides out of the distal insertion tube opening and makes sealing contact with an inner wall portion of the generally cylindrical body.

[0046] Many drug reservoirs used in injection or infusion therapy have siliconized internal surfaces to improve frictional engagement with the piston. By using an insertion tube, the piston slides along the internal surface of the drug reservoir, and as a result can be inserted without scraping off the silicone. Scraping off the silicone can interact with the liquid drug substance over time, causing precipitation, rendering the product useless.

[0047] For the avoidance of doubt, in this context, the terms "distal" and "proximal" refer to a position on or a direction along a drug delivery device or needle unit, with "distal" referring to the drug exit end and "proximal" referring to the end opposite the drug exit end.

[0048] Reference herein to a particular aspect or embodiment (e.g., "aspect," "first aspect," "one embodiment," "exemplary embodiment," etc.) expresses that the particular feature, structure, or characteristic described in connection with each aspect or embodiment is included in or inherent to at least that aspect or embodiment of the invention, but not necessarily in or among all aspects or embodiments of the invention. However, it is emphasized that any combination of the various features, structures, and / or characteristics described in connection with the invention is encompassed by the invention, unless expressly stated herein or clearly contradicted by context.

[0049] The use of any and all examples or exemplary language (such as, for example, etc.) in the text is intended merely to better clarify the invention and does not limit the scope of the invention unless otherwise claimed. Moreover, no language or phraseology in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0050] In the following the invention is further explained with reference to the drawings. [Brief description of the drawings]

[0051] [Figure 1] FIG. 1 is a longitudinal cross-sectional view of a drug reservoir according to an exemplary embodiment of the present invention in a pre-use state. [Figure 2a-2c] 2a-c are graphs illustrating the application of initial force to the rear reservoir piston with no proximal gas volume and with two different proximal gas volumes, respectively. [Diagram 3] FIG. 3 is a principle schematic of a process for filling a drug reservoir with two liquid volumes. [Figure 4] FIG. 4 is a longitudinal cross-sectional view of an exemplary drug delivery device that uses the drug reservoir of FIG. [Diagram 5] FIG. 5 shows a longitudinal cross-section of the drug delivery device in a ready-to-use state. [Figure 6-10] 6 to 10 are longitudinal cross-sectional views of the drug delivery device in different pre-use states. [Figure 11] FIG. 11 is a longitudinal cross-sectional view of the drug delivery device in an empty state after use.

[0052] In the drawings, like structures are primarily identified by like reference numbers. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0053] When / if relative expressions such as "up" and "down", "left" and "right", "horizontal" and "vertical", "clockwise" and "counterclockwise" are used below, they refer to the attached figures and do not necessarily refer to actual usage situations. The figures shown are schematic and therefore their relative dimensions as well as the configuration of different structures are intended to serve illustrative purposes only.

[0054] 1 is a longitudinal cross-sectional view of a drug reservoir 1 according to an exemplary embodiment of the present invention. The drug reservoir 1 is shown in a pre-use state, i.e., as supplied by the manufacturer (but without a rigid needle protector).

[0055] The drug reservoir 1 has a generally cylindrical reservoir body 2 having a bypass channel 3 and a narrow distal end portion 4. An injection needle 5 is fixed to the distal end portion 4 and establishes fluid communication to the reservoir outlet 6. A front piston 8 is disposed within the reservoir body 2 between the reservoir outlet 6 and the open proximal end 7, whereby a front chamber 10 is defined by the reservoir outlet 6, a front portion of the reservoir body 2 including the bypass channel 3, and the front piston 8. A rear piston 9 is disposed within the reservoir body 2 between the front piston 8 and the open proximal end 7, whereby a rear chamber 11 is defined by the front piston 8, a central portion of the reservoir body 2, and the rear piston 9. The rear piston 9 has a recess 13 adapted to receive an end portion of a piston rod (not shown).

[0056] The front chamber 10 holds a first liquid substance 18 and the rear chamber 11 holds a second liquid substance 19, as well as a proximal gas volume 12, sketched in the form of gas bubbles within the liquid medicament 19. The proximal gas volume 12 is purposefully incorporated in the rear chamber 11 to reduce the force required to effect ejection of the reservoir contents through the injection needle 5, as will be explained in more detail below. In this example, the proximal gas volume is 15 μl.

[0057] When the piston rod is inserted into the recess 13 and a distally directed force is applied to the rear piston 9, the rear piston 9 will remain in its initial position until the applied force exceeds a certain threshold required to overcome static friction at the contact interface between the sealed outer surface of the rear piston 9 and the inner wall of the reservoir body 2.

[0058] Figures 2a to 2c show the initial force required to operate the rear piston 9 in three different cases, where the graph in Figure 2a is the force profile for a drug reservoir with no proximal gas volume, the graph in Figure 2b is the force profile for a drug reservoir with a proximal gas volume of 15 μl, and the graph in Figure 2c is the force profile for a drug reservoir with a proximal gas volume of 20 μl.

[0059] In dual-chamber drug reservoirs with no proximal gas volume in the rear chamber, the liquid acts as a rigid connection between the front and rear pistons. The single force peak, F0, in Figure 2a reflects the fact that in such devices, due to the incompressibility of the liquid, moving the rear piston requires moving the front piston as well. Experiments show that a release force of approximately 15 N is required to overcome the static friction of a system containing both pistons.

[0060] In contrast, as the graph in FIG. 2b shows, when a given proximal gas volume of 15 μl is present in the rear chamber 11, the gas adds some flexibility to the system, which results in the rear piston 9 releasing before the front piston 8. In this case, as the proximal gas volume is compressed, a small force F of just under 7 N is exerted. r,15 is needed to operate the rear piston 9. Then the gas is fully compressed and the resulting liquid / gas system is such that the front piston 8 reaches the next force peak, F f,15 The force rises as the front piston 8 acts as a rigid connection between the two pistons until it is released at (approximately 11 N). The sudden drop in force level after release of the front piston 8 reflects the transition from static to kinetic friction between the piston and the inner reservoir wall. As the liquid in the front chamber 10 becomes pressurized and is forced through the small lumen of the needle 5 with continued movement of the front piston 8, the force increases somewhat again due to the flow resistance of the needle 5, but does not approach the level of F0.

[0061] In FIG. 2c, the difference is even more striking. A graph showing the results of an experiment with a proximal gas volume of 20 μl in the rear chamber 11 shows a comparable force F f,20 , and a significantly smaller force F, which is in the region of 9 N and later releases the front piston 8. r,20Overall, as the graph shows, when a proximal gas volume of at least 15 μl is present in the rear chamber 11, the maximum force required to initiate and support the drug expulsion action is reduced because the flexibility provided by that gas volume allows the rear piston 9 to release from the reservoir wall separately from the front piston 8.

[0062] 3 is a principle schematic diagram of a process for filling a drug reservoir 1 with two liquid volumes. From left to right, the process steps include holding the drug reservoir 1 in an upright position with the injection needle 5 sealed by the needle plug 41 and taking a predetermined volume of a first liquid substance 18 into the reservoir body 2 through the proximal end 7.

[0063] Upon filling the distal portion of the reservoir body 2 to a level where the bypass channel 3 is covered, the drug reservoir 1 is placed in a first subatmospheric pressure environment 100. The front piston 8 is disposed in radial compression in an insertion tube 80 having an inner diameter smaller than that of the reservoir body 2, which is taken into the reservoir body 2 through the proximal end 7, in particular without contacting the inner wall of the reservoir body 2. The front piston 8 is then forced through the insertion tube 80 and expands in contact with the inner wall of the reservoir body 2 just above the free surface of the first liquid substance 18, thereby establishing a front chamber 10, after which the drug reservoir 1 is re-exposed to normalized pressure conditions. The negative pressure in the front chamber 10 due to the insertion of the front piston 8 into the first subatmospheric pressure environment 100 moves the front piston 8 towards the first liquid substance 18, closing the gap with its free surface.

[0064] A predetermined volume of second liquid substance 19 is drawn into reservoir body 2 through proximal end 7, filling the space above front piston 8. Drug reservoir 1 is then placed into a second sub-atmospheric environment 200 of ambient gas, where insertion tube 80 carrying rear piston 9 in a radially compressed state is drawn into reservoir body 2 in a manner similar to that described above. At this time, pressure is controlled such that when rear piston 9 is placed into reservoir body 2, thereby establishing rear chamber 11, and drug reservoir 1 is thereafter re-exposed to normalized pressure conditions, the volume of ambient gas remains in rear chamber 11 as a free gas volume within a volume range having a predetermined minimum value.

[0065] 4 is a longitudinal cross-sectional view of a drug reservoir 1 forming part of an exemplary special purpose auto-injector 20. The auto-injector 20 comprises a tubular housing 21, proximally closed by a lateral end wall 22, containing a drug ejection mechanism including a piston rod 30 having a head portion 31 inserted within the recess 13 and a shoulder portion 32 adapted to apply a distally directed force to the rear piston 9.

[0066] A pair of snap arms 24 extend distally from the lateral end wall 22 into the interior of the housing 21 terminating in respective detents 26 having "v" shaped interfaces 27 configured to engage corresponding recesses 33 in the piston rod 30. Each snap arm 24 has a proximal carving 25 that provides flexibility and allows radial deflection of the detents 26.

[0067] A pretensioned compression spring 65 is disposed within the piston rod 30 and is supported proximally by a central pin 23 extending distally from the lateral end wall 22. The spring 65 is adapted to act between a distal end portion of the piston rod 30 and the lateral end wall 22.

[0068] The drug reservoir 1 is held within the housing 21 and is distally closed by a rigid needle protector 40 carrying a needle plug 41. An elongated sleeve 50 is disposed concentrically with and between the drug reservoir 1 and the housing 21. The sleeve 50 is axially displaceable relative to the housing 21 biased in a proximal direction by a sleeve spring 75 and includes a radially enlarged proximal end portion 51 having a narrow adjacent section 53. In the illustrated pre-use state of the auto-injector 20, the sleeve 50 is in its maximum extended position relative to the housing 21 and the proximal end portion 51 is axially aligned with the detent 26, physically preventing the interface portion 27 from leaving the recess 33. The auto-injector 20 is therefore safely cocked as the spring 65 is maintained in a pre-tensioned state since the piston rod 30 cannot undergo axial movement relative to the housing 21.

[0069] 5 is a longitudinal cross-sectional view of the auto-injector 20 in a ready-to-use state after removal of the rigid needle protector 40 and the needle plug 41. The sleeve 50 is still in its maximum extended position relative to the housing 21, where the distal sleeve end portion 52 covers the injection needle 5 and thus protects the user from accidental needle stick injuries. The distal sleeve end portion 52 has a sleeve rim 54 adapted to abut and be pressed against the user's skin at the desired injection site during release of the medicament.

[0070] 6-11 show the step-by-step dose ejection procedure of the auto-injector 20. First, the user places the sleeve rim 54 in contact with the desired skin location (not shown) and presses the housing 21 against the skin. This causes the distal sleeve end portion 52 to compress the sleeve spring 75 as the housing 21 and sleeve 50 undergo a relative axial movement from the mutual position shown in FIG. 5 to that shown in FIG. 6. In essence, the sleeve 50 is displaced proximally relative to the housing 21, which causes the respective enlarged proximal end portions 51 to slide proximally along the prongs 26. At some point, when the distal sleeve end portions 52 are pushed back sufficiently that the tip of the injection needle 5 is exposed and penetrates the skin surface, the sleeve 50 reaches a position relative to the snap arm 24 where the enlarged proximal end portions 51 are no longer axially aligned with the prongs 26. Instead, the prongs 26 are axially aligned with the narrow adjacent section 53, thereby no longer preventing radial displacement.

[0071] The pre-tensioned spring 65 provides a distally oriented bias against the piston rod 30 at all times, such that when the pawl 26 is no longer radially fixed, the axial force from the spring 65 and the respective configurations of the interface 27 and recess 33 cause the snap arm 24 to deflect radially about the proximal carving 25, causing the pawl 26 to disengage from the piston rod 30 and the resulting release of the spring 65. This is shown in FIG.

[0072] The initial result of the release of the spring 65 can also be seen in Figure 7. The presence of the proximal gas volume 12 allows for a small compression of the rear chamber 11, so that as the force from the expansion spring 65 pushes the piston rod 30 forward, the front piston 8 remains stationary while the rear piston 9 is released from the inner wall of the reservoir body 2. Thus, the spring 65 at this point only has to overcome the static friction between the rear piston 9 and the reservoir body 2 (and not the static friction between the front piston 8 and the reservoir body 2). In Figure 7, the compression of the rear chamber 11 is indicated by the reduced size of the proximal gas volume 12.

[0073] When the proximal gas volume 12 is fully compressed, the contents of the rear chamber 11 transfer the force from the spring 65 to the front piston 8 which is then released and moves distally within the reservoir body 2 along with the rear piston 9, the second liquid substance 19 and the compressed proximal gas volume. The rear chamber 11, as such, is thus displaced within the reservoir body 2 until the volume of the first liquid substance 18 is forced through the infusion needle 5 and the front piston 8 reaches the bypass channel 3, as shown in FIG. 8, where, as the spring 65 continues to expand, the second liquid substance 19 is forced into the bypass channel 3 and past the front piston 8.

[0074] As the rear piston 9 approaches the front piston 8, the rear chamber 11 eventually compresses and the second liquid substance 19 is transferred to the front chamber 10 where it mixes with the remainder of the first liquid substance 18. Figure 9 shows the state of the auto-injector 20 immediately after compression of the rear chamber 11.

[0075] Now, the mixed first and second liquid substances 18, 19 are expelled from the front chamber 10 through the injection needle 5 which, under the influence of the piston rod 30 and the spring 65, follows the rear piston 9, pushing the front piston 8 further distally within the reservoir body 2. In Figure 10, the front piston 8 covers the distal end of the bypass channel 3, thus sealing the front chamber 10 in the proximal direction.

[0076] Ejection of medication continues until the front piston 8 reaches the retraction of the reservoir body 2 at the reservoir outlet 6, after which the user moves the housing 21 away from the injection site, thereby withdrawing the needle 5 from the skin. When pressure between the skin surface and the sleeve rim 74 is released, the sleeve spring 75 expands, urging the sleeve 50 distally relative to the housing 21 until the distal sleeve end portion 52 again covers the needle 5. The auto-injector 20 as shown in Figure 11 is now in a post-use state and may be safely discarded without the risk of accidental needle stick injuries.

Claims

1. A drug reservoir (1), a reservoir body (2) extending between an outlet end (4) and a proximal end (7); a front piston (8) disposed in a pre-use position within said reservoir body (2) between said outlet end (4) and said proximal end (7); a rear piston (9) disposed within the reservoir body (2) between the front piston (8) and the proximal end (7); - a distal chamber (10) defined by said outlet end (4), a first portion of said reservoir body (2) and said front piston (8), said distal chamber (10) holding a first content (18); - a proximal chamber (11) defined by said front piston (8), a second part of said reservoir body (2) and said rear piston (9), said proximal chamber (11) holding a second content (12, 19) comprising a proximal liquid volume (19); - bypass means (3) allowing fluid flow past said front piston (8) in its advanced position in said reservoir body (2); The drug reservoir (1), further comprising a proximal gas volume (12), wherein said second contents (12, 19) are within a volume range having a predetermined minimum value.

2. 2. The drug reservoir of claim 1, wherein the predetermined minimum value is 15 μl.

3. The drug reservoir of claim 1 , wherein the volume range is a predetermined closed volume range.

4. 4. The drug reservoir of claim 3, wherein the predetermined closed volume range is: [15 μl; 200 μl].

5. 4. The drug reservoir of claim 3, wherein the predetermined closed volume range is: [20 μl; 50 μl].

6. The drug reservoir of any one of claims 1 to 5, wherein the first content (18) comprises a distal liquid volume and a distal gas volume, the distal gas volume being smaller than the proximal gas volume (12).

7. The drug reservoir of any one of claims 1 to 6, wherein the proximal gas volume (12) comprises air.

8. The drug reservoir of any one of claims 1 to 6, wherein the proximal gas volume (12) comprises an inert gas.

9. The drug reservoir of any one of claims 1 to 8, further comprising a hollow needle (5) fixedly disposed at the outlet end (4) and in fluid connection with the distal chamber (10).

10. A drug delivery device (20), comprising: - a drug reservoir (1) according to any one of claims 1 to 9, - a dose ejection structure for pressurizing said proximal chamber (11), the dose ejection structure comprising an actuatable piston rod (30) adapted to transmit an ejection force to said rear piston (9).

11. 11. The drug delivery device of claim 10, further comprising a housing (21) extending along a reference axis, wherein the dose ejection structure is powered by a spring member (65) operably connected to the piston rod (30) and adapted to store releasable energy to urge the piston rod (30) towards the outlet end (4).

12. a retaining structure (24, 26, 27) which, when activated, holds said spring member (65) in a tensioned state; a sleeve member (50) extending axially along a portion of said housing (21) and including release structures (51, 53); 12. The drug delivery device of claim 11, wherein the sleeve member (50) is configured to be displaced proximally relative to the housing (21) and the retaining structures (24, 26, 27) from a first position, in which the retaining structures (24, 26, 27) are usable, to a second position, in which the retaining structures (24, 26, 27) are disabled by the release structures (51, 53), resulting in stored energy being released from the spring member (65).

13. A method of filling a drug reservoir (1) comprising a generally cylindrical body (2) having a bypass section (3), a closed outlet end (4), and an open end (7), comprising the steps of: (i) disposing said drug reservoir (1) at least substantially vertically with said open end (7) facing upwards; (ii) introducing a first liquid volume (18) into the drug reservoir (1) through said open end (7) such that a first internal portion of said generally cylindrical body (2), including said bypass section (3), is covered by liquid at a vertical position of said drug reservoir (1) with said open end (7) facing upwards; (iii) inserting a first piston (8) into said generally cylindrical body (2) in a first sub-atmospheric pressure environment (100) to a first piston position at least substantially adjacent a free surface of said first liquid volume (18), thereby establishing a front chamber (10) for holding said first liquid volume (18); (iv) introducing a second liquid volume (19) into the drug reservoir (1) through the open end (7); (v) inserting a second piston (9) into said generally cylindrical body (2) in a second sub-atmospheric pressure environment (200) of ambient gas to a second piston position, thereby establishing a rear chamber (11), said second piston position being determined such that said rear chamber (11) holds said second liquid volume (19) and a rear chamber gas volume (12) is within a volume range having a predetermined minimum value.

Citation Information

Patent Citations

  • Automatic injector with cartridge having separate sequentially injectable medicaments

    US4394863A

  • Mixing device with piston coupling arrangement

    WO2010139793A1